- Home
- / Immune Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Immune Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2022-08-03
Market Capitalization
$1.6 M
2022-08-03
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 944.0K | 7.8M | 19.0K | 2.0K | |||
| Cost of goods sold | 692.0K | 403.0K | |||||
| Gross profit | 252.0K | 7.4M | |||||
| Gross profit margin, % | 26.7% | 94.8% | |||||
| General and administrative expense | 6.5M | 4.6M | 5.4M | 10.7M | 9.8M | 6.4M | 6.6M |
| Operating expense total | 14.3M | 8.0M | 12.3M | 23.6M | 17.2M | 25.0M | 19.9M |
| Depreciation and amortization | 16.0K | ||||||
| EBIT | (14.1M) | (606.0K) | (9.0M) | (16.4M) | (15.7M) | (27.3M) | (12.1M) |
| EBIT margin, % | -1488.7% | -7.8% | -47368.4% | -818150.0% | |||
| Interest income | 12.0K | 4.0K | |||||
| Interest expense | 1.3M | 1.2M | |||||
| Pre tax profit | (15.7M) | (2.6M) | (5.7M) | (23.5M) | (17.2M) | (37.5M) | (19.9M) |
| Income tax expense | 4.0K | 2.0K | 11.0K | (4.9M) | (2.0M) | ||
| Net Income | (15.7M) | (2.6M) | (5.8M) | (23.5M) | (17.2M) | (32.7M) | (17.9M) |